Cargando…
Personalised Medicine—Implementation to the Healthcare System in Europe (Focus Group Discussions)
Background: Personalized medicine (PM) is an approach based on understanding the differences between patients with the same disease and represents a change from the “one size fits all” concept. According to this concept, appropriate therapies should be selected for specific groups of patients. PM ma...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058568/ https://www.ncbi.nlm.nih.gov/pubmed/36983562 http://dx.doi.org/10.3390/jpm13030380 |
_version_ | 1785016662796271616 |
---|---|
author | Stefanicka-Wojtas, Dorota Kurpas, Donata |
author_facet | Stefanicka-Wojtas, Dorota Kurpas, Donata |
author_sort | Stefanicka-Wojtas, Dorota |
collection | PubMed |
description | Background: Personalized medicine (PM) is an approach based on understanding the differences between patients with the same disease and represents a change from the “one size fits all” concept. According to this concept, appropriate therapies should be selected for specific groups of patients. PM makes it possible to predict whether a particular therapy will be effective for a particular patient. PM will still have to overcome many challenges and barriers before it can be successfully implemented in healthcare systems. However, it is essential to remember that PM is not a medical revolution but an evolution. Methods: Three focus groups were conducted, to achieve the purpose of this study, which was to identify the barriers and facilitators existing to the implementation of PM and to highlight existing practices in European countries. Focus group discussions covered the areas of barriers and facilitators to the implementation of personalized medicine. Results: This section describes the results of the focus groups that covered the areas of barriers and facilitators of personalized medicine implementation. Conclusions: Personalized medicine faces many challenges and barriers before it can be successfully implemented in health systems. The translation of PM to European countries, differences in regulations, high costs of new technologies, and reimbursement are the reasons for the delay in PM implementation. |
format | Online Article Text |
id | pubmed-10058568 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100585682023-03-30 Personalised Medicine—Implementation to the Healthcare System in Europe (Focus Group Discussions) Stefanicka-Wojtas, Dorota Kurpas, Donata J Pers Med Article Background: Personalized medicine (PM) is an approach based on understanding the differences between patients with the same disease and represents a change from the “one size fits all” concept. According to this concept, appropriate therapies should be selected for specific groups of patients. PM makes it possible to predict whether a particular therapy will be effective for a particular patient. PM will still have to overcome many challenges and barriers before it can be successfully implemented in healthcare systems. However, it is essential to remember that PM is not a medical revolution but an evolution. Methods: Three focus groups were conducted, to achieve the purpose of this study, which was to identify the barriers and facilitators existing to the implementation of PM and to highlight existing practices in European countries. Focus group discussions covered the areas of barriers and facilitators to the implementation of personalized medicine. Results: This section describes the results of the focus groups that covered the areas of barriers and facilitators of personalized medicine implementation. Conclusions: Personalized medicine faces many challenges and barriers before it can be successfully implemented in health systems. The translation of PM to European countries, differences in regulations, high costs of new technologies, and reimbursement are the reasons for the delay in PM implementation. MDPI 2023-02-21 /pmc/articles/PMC10058568/ /pubmed/36983562 http://dx.doi.org/10.3390/jpm13030380 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Stefanicka-Wojtas, Dorota Kurpas, Donata Personalised Medicine—Implementation to the Healthcare System in Europe (Focus Group Discussions) |
title | Personalised Medicine—Implementation to the Healthcare System in Europe (Focus Group Discussions) |
title_full | Personalised Medicine—Implementation to the Healthcare System in Europe (Focus Group Discussions) |
title_fullStr | Personalised Medicine—Implementation to the Healthcare System in Europe (Focus Group Discussions) |
title_full_unstemmed | Personalised Medicine—Implementation to the Healthcare System in Europe (Focus Group Discussions) |
title_short | Personalised Medicine—Implementation to the Healthcare System in Europe (Focus Group Discussions) |
title_sort | personalised medicine—implementation to the healthcare system in europe (focus group discussions) |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058568/ https://www.ncbi.nlm.nih.gov/pubmed/36983562 http://dx.doi.org/10.3390/jpm13030380 |
work_keys_str_mv | AT stefanickawojtasdorota personalisedmedicineimplementationtothehealthcaresystemineuropefocusgroupdiscussions AT kurpasdonata personalisedmedicineimplementationtothehealthcaresystemineuropefocusgroupdiscussions |